This section hosts guidelines, manuals and toolkits to strengthen public health practice.
Coronavirus disease 2019 (COVID-19) infection causes a severe proinflammatory storm and lung infection, with more than 200 million confirmed cases and 5 million fatalities worldwide. Over the past two years, a number of vaccinations have been produced to slow the COVID-19 virus's quick spread. Despite this, COVID-19 continues to inflict numerous permanent organ injuries. As a result, cell therapy is receiving a lot of attention in the management of organ damage in this terrible COVID-19 pandemic. Mesenchymal stem cells (MSCs), for instance, have shown promise in COVID-19 patients. Stem cells have been found to be useful in managing COVID-19-induced unfavorable effects by inhibiting cytokine storm and hyperinflammatory syndrome with concurrent tissue regeneration capacity, according to preclinical and clinical data. The data that is now available on the use of stem cells for COVID-19 are discussed in this review.